Clinical Trial Finder

• Restore CFTR FunctionEnrolling

  Study to evaluate VX-121 in adults 18 years and older with cystic fibrosis , protocol number Vertex VX-18-121-101

  This study will look at the safety, tolerability, and effectiveness of the drug VX-121, a drug intended to help CFTR function closer to normal.

  • Age:

    18 Years and Older

  • Mutation(s):

    Two Copies F508del or One Copy F508del

  • FEV1% Predicted:

    40 to 90%

  • Number of Visits:

    10

  • Length of Participation:

    17 weeks

• Mucociliary ClearanceEnrolling

  Study of BI 1265162, a mucus clearance drug, in teens and adults with CF , protocol number BI 1399-0003

  This study will look at the safety and effectiveness of BI 1265162, a drug intended to improve the clearance of mucus from the lungs. This study is for people with CF ages 12 and older.

  • Age:

    12 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40 to 90%

  • Number of Visits:

    5

  • Length of Participation:

    7 weeks

• Anti-InflammatoryEnrolling

  Phase 2 study of lenabasum in people with CF ages 12 and older , protocol number Corbus JBT101-CF-002

  This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the potential anti-inflammatory drug lenabasum and will use a placebo control.

  • Age:

    12 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40 to 100%

  • Number of Visits:

    10

  • Length of Participation:

    32 weeks

• Anti-InfectiveEnrolling

  Phase 3 study of inhaled vancomycin in adults and children 6 years and older with cystic fibrosis , protocol number Savara SAV005-04

  This study is taking place at multiple care centers across the U.S. It will look at the effectiveness of the inhaled drug vancomycin in adults and children 6 years and older with cystic fibrosis and positive cultures for methicillin-resistant Staphylococcus aureus (MRSA).

  • Age:

    6 Years to 21 Years

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    30 to 90%

  • Number of Visits:

    13

  • Length of Participation:

    12 months

• ObservationalEnrolling

  Sweat chloride observational study , protocol number CHEC-OB-17

  This study is taking place at multiple care centers across the U.S. It will look at sweat chloride concentration in people who are currently taking CFTR modulators.

  • Age:

    4 Months and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    1

  • Length of Participation:

    1 days

• OtherEnrolling

  Study of SPI-1005 in people with CF ages 18 and older , protocol number Sound Pharma SPI-3005-501.2

  This study will test the safety and tolerability of SPI-1005, a drug intended to prevent and treat hearing loss caused by aminoglycosides.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40% or greater

  • Number of Visits:

    6

  • Length of Participation:

    49 days

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.